ctDNA SNORD3F Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer

被引:0
|
作者
Liu, Bin [1 ]
Zhao, Bingtian [1 ]
Yin, Yan [1 ]
Jiang, Yan [1 ]
Feng, Xue [1 ]
Wang, Lei [1 ]
Zhai, Liang [1 ]
Liu, Guangxin [1 ]
Shi, Dongsheng [1 ]
Qin, Jianwen [1 ]
机构
[1] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2024年 / 16卷
关键词
ctDNA; EGFR; DNA methylation; lung cancer; snoRNA; SNORD3F; CIRCULATING TUMOR DNA; GEFITINIB RESISTANCE; METHYLATION; MUTATIONS; NSCLC;
D O I
10.2147/CMAR.S474241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: DNA methylation plays a regulatory role in the oncogenesis and tumor progression and is valuable in the diagnosis and prognosis of cancer. While circulating tumor DNA (ctDNA) is widely used in the detection of oncogenic mutations and the guidance of treatment in advanced non-small cell lung cancer (NSCLC), studies of ctDNA methylation remains insufficient. We aim to investigate the methylation profiles of ctDNA in patients with advanced NSCLC undergoing EGFR-tyrosine kinase inhibitor (EGFRTKI) therapy and to discover novel biomarkers with predictive or prognostic value. Patients and Methods: We recruited 49 patients with EGFR-mutated advanced NSCLC undergoing EGFR-TKI as first-line treatment. Utilizing next-generation sequencing, we examined the somatic mutations and methylation signatures within the tumorassociated genomic regions of ctDNA from pre-treatment blood. Subsequently, we explored the association of these molecular features with the patients' response to therapy and their progression-free survival (PFS). Results: Genomic mutation profiling revealed no significant association of PFS or best overall response (BOR) and ctDNA status. Evaluation of ctDNA methylation showed a negative correlation between the methylation of small nucleolar RNA (snoRNA) genes and PFS (R=-0.31, P=0.043). Furthermore, high-level methylation of SNORD3F was associated with poorer PFS (mPFS 346d vs 243d, HR 0.49, 95% CI 0.24-0.93, P=0.029). Conclusion: Our study explored the prognostic value of ctDNA methylation in patients with advanced NSCLC undergoing targeted therapies and first revealed the predictive role of SNORD3F.
引用
收藏
页码:1405 / 1416
页数:12
相关论文
共 50 条
  • [41] Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
    Zhou, Bo
    Nie, Jun
    Yang, Weidong
    Huang, Chenhong
    Huang, Ye
    Zhao, Hongfei
    ONCOLOGY LETTERS, 2016, 11 (02) : 1413 - 1417
  • [42] Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Kogure, Yoshihito
    Saka, Hideo
    Oki, Masahide
    Saito, Toshiki I.
    Ahmed, Shimaa Nour Moursi
    Kitagawa, Chiyoe
    Imaizumi, Kazuyoshi
    PLOS ONE, 2015, 10 (08):
  • [43] The Abundance of EGFR Mutations Could Be More Better Predictor for EGFR-TKI Therapy in Advanced Non-Small Cell Lung Cancer
    Li, Xuefei
    Su, Chunxia
    Zhao, Chao
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S310 - S310
  • [44] The Timing of Best Tumor Response and Patterns of Disease Progression in Non-small Cell Lung Cancer Treated with EGFR TKI
    Tang, Y.
    Wu, K.
    Wang, B.
    Xu, X.
    Zhang, M.
    Ma, S.
    Xia, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E534 - E535
  • [45] Sunitinib in treatment of advanced non-small cell lung cancer after failure of multiregimens of chemotherapy and EGFR-TKI
    Liu, X.
    Wang, W.
    Li, J.
    Tang, C.
    Yu, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitor (TKI)
    Sun, Jong-Mu
    Park, Min Jae
    Yi, Jun Ho
    Kong, Jeehyun
    Kim, Jung-A
    Lee, Soohyeon
    Yun, Lin A.
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S716 - S716
  • [47] EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer
    Oshima, Yasuo
    Tanimoto, Tetsuya
    Yuji, Koichiro
    Tojo, Arinobu
    JAMA ONCOLOGY, 2018, 4 (08) : 1112 - 1115
  • [48] A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Wehler, T.
    Hirsh, V.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1043 - S1043
  • [49] Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer
    Ge, Liangqing
    Shi, Ruizheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (07): : 10330 - 10339
  • [50] Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI
    Tang, Yi
    Xia, Bing
    Xie, Ruifei
    Xu, Xiao
    Zhang, Minna
    Wu, Kan
    Wang, Bing
    Ma, Shenglin
    LUNG CANCER, 2020, 140 : 65 - 70